On March 20, 2018 OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, reported that Dr. Jonathan Head, Chief Executive Officer at OncBioMune, will present a poster at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) ("AACR") Annual Meeting taking place April 14 – 18, 2018 in Chicago, Illinois (Press release, Oncbiomune, MAR 20, 2018, View Source [SID1234524911]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The clinical trial abstract, entitled "Interim results of a phase 1a clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer therapeutic vaccine in PSA defined biochemical recurrent prostate cancer patients," highlights the safety and efficacy of ProscaVax, the Company’s novel immunotherapeutic cancer vaccine, as evidenced through data collected in the study. Based upon the impressive body of data from the Phase 1a portion of the study, OncBioMune is forgoing the planned 1b portion and moving into two, separate Phase 2 studies of ProscaVax for late-stage and early-stage prostate cancer, respectively.

The abstract also will be published online in the 2018 Proceedings of the AACR (Free AACR Whitepaper).

Details of the abstract are as follows:

Session Title: Phase I Clinical Trials 2
Session Date and Time: Monday Apr 16, 2018 8:00 AM – 12:00 PM
Session Location: McCormick Place South, Hall A, Poster Section 42
Poster Board Number: 14